BridgeBio Pharma (FRA:2CL) Beta: 2.1365 (As of Jun. 26, 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
66 GF Score
Price €60.30
GF Value €124.34
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is BridgeBio Pharma Beta?

BridgeBio Pharma FRA:2CL +0.03% 66 Beta is 2.1365 as of Jun. 26, 2026. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €124.34 (Possible Value Trap). The stock has 7 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), BridgeBio Pharma's Beta is 2.1365.


BridgeBio Pharma  (FRA:2CL) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BridgeBio Pharma Beta Related Terms


BridgeBio Pharma Beta Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma Beta Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 0.65 1.58 0.39 -0.50

BridgeBio Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.59 1.59 2.20 -0.50 2.42

FRA:2CL vs EXEL, IONS, SMMT: Beta Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Pharma Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Beta distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Beta falls into.


FRA:2CL
66GF Score
BridgeBio Pharma Inc FRA:2CL
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Pharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.1365 mean?
BridgeBio Pharma (FRA:2CL) has a Beta of 2.1365 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BridgeBio Pharma and its competitors.
Is BridgeBio Pharma's Beta too high?
BridgeBio Pharma's current Beta is 2.1365. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Beta compare to EXEL and IONS?
BridgeBio Pharma's Beta of 2.1365 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BridgeBio Pharma and its competitors. BridgeBio Pharma's current Beta is 2.1365. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €124.34, compared to a current price of €60.30 — trading 51.5% below its estimated fair value. The current Beta is 2.1365. BridgeBio Pharma's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Beta is 2.1365 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €60.30 is trading 51.5% below its estimated GF Value™ of €124.34. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Beta: 2.1365
  • GF Value™: €124.34 vs. price of €60.30 (51.5% below fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score

Get the complete analysis for FRA:2CL

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.30
Price
€124.34
GF Value